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366Background: Several single-institution series have demonstrated that compared with open thoracotomy, video-
assisted thoracoscopic lobectomy may be associated with fewer postoperative complications. In the absence of
randomized trials, we queried the Society of Thoracic Surgeons database to compare postoperative mortality
and morbidity following open and video-assisted thoracoscopic lobectomy. A propensity-matched analysis using
a large national database may enable a more comprehensive comparison of postoperative outcomes.
Methods: All patients having lobectomy as the primary procedure via thoracoscopy or thoracotomy were iden-
tified in the Society of Thoracic Surgeons database from 2002 to 2007. After exclusions, 6323 patients were iden-
tified: 5042 having thoracotomy, 1281 having thoracoscopy. A propensity analysis was performed, incorporating
preoperative variables, and the incidence of postoperative complications was compared.
Results: Matching based on propensity scores produced 1281 patients in each group for analysis of postoperative out-
comes. After video-assisted thoracoscopic lobectomy, 945 patients (73.8%) had no complications, compared with 847
patients (65.3%) who had lobectomy via thoracotomy (P< .0001). Compared with open lobectomy, video-assisted
thoracoscopic lobectomy was associated with a lower incidence of arrhythmias [n¼ 93 (7.3%) vs 147 (11.5%); P¼
.0004], reintubation [n ¼ 18 (1.4%) vs 40 (3.1%); P ¼ .0046], and blood transfusion [n ¼ 31 (2.4%) vs n ¼ 60
(4.7%); P ¼ .0028], as well as a shorter length of stay (4.0 vs 6.0 days; P< .0001) and chest tube duration (3.0 vs
4.0 days; P< .0001). There was no difference in operative mortality between the 2 groups.
Conclusions: Video-assisted thoracoscopic lobectomy is associated with a lower incidence of complications
compared with lobectomy via thoracotomy. For appropriate candidates, video-assisted thoracoscopic lobectomy
may be the preferred strategy for appropriately selected patients with lung cancer. (J Thorac Cardiovasc Surg
2010;139:366-78)Earn CME credits at
http://cme.ctsnetjournals.org
Thoracoscopic lobectomy, also referred to as video-assisted
thoracoscopic surgery (VATS) lobectomy, is associated with
many outcome advantages compared with lobectomy by tho-
racotomy.1-11 Recently, it has been proposed that surgical out-
comes are superior with thoracoscopic lobectomy, based on
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The Journal of Thoracic and Cardiovascular Surgseries.12-14 However, to date there is no large randomized trial
comparing VATS lobectomy to lobectomy by thoracotomy.
In the absence of robust data from phase III trials, we
queried the Society of Thoracic Surgeons (STS) General
Thoracic Database (STS-GTD) to compare the postoperative
mortality and morbidity following open and thoracoscopic
lobectomy. A propensity-matched analysis using a large
national database may enable a more powerful and compre-
hensive comparison of postoperative outcomes.
PATIENTS AND METHODS
Data Source
The STS has maintained a prospective database of patients having car-
diothoracic surgery in the United States since 1987 with the database ex-
panded in 1999 to include general thoracic surgery operations. At the
time of the latest report, there were more than 80 participating sites (hos-
pitals, group practices, or individual surgeons). Harvested data are main-
tained and analyzed by the Duke Clinical Research Institute in
compliance with the Health Insurance Portability and Accountability Act
of 1996. Variables are collected on a standardized data form that includes
information about patient demographics, medical history, surgical
procedures, cancer staging, and outcome (http://www.ctsnet.org/file/
ThoracicDCFV2_07_Nonannotated.pdf). Institutional Review Boards of
each participating site approved the use of this database for quality
improvement research. The collection and maintenance of the general
thoracic surgery portion of the database has been described elsewhere.15,16ery c February 2010
FIGURE 1. Lobectomy by thoracotomy or thoracoscopy by year in Soci-
ety of Thoracic Surgeons (STS) general thoracic database.
Abbreviations and Acronyms
STS ¼ Society of Thoracic Surgeons
STS-GTD ¼ Society of Thoracic Surgeons General
Thoracic Database
VATS ¼ video-assisted thoracoscopic surgery
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The study population consists of patients having lobectomy as the primary
procedure at STS-participating hospitals between January 1, 2002, and
December 31, 2007. All data were collected using STS-GTSD 1.30, 1.31,
2.06, 2.061, and 2.07 data collection forms. Patients were excluded from the
study if they had prior thoracic surgery, a pulmonary procedure other than lo-
bectomy, an approach other than thoracoscopy and thoracotomy was listed, if
both thoracoscopy and thoracotomy were listed as the approach, and if data
were missing on age (6 patients, 0.13% excluded from analysis) and gender
(17 patients, 0.27% excluded from analysis). Six thousand three hundred
twenty-three patients were identified (5042 having thoracotomy, 1281 having
thoracoscopy; Appendix Table 1). The distribution of techniques used for
lobectomies performed during that time interval is shown in Figure 1.Data Collection and Statistical Model
Data collected for each patient included continuous variables [age at time of
surgery, body mass index with missing values (9.2%missing) entered accord-
ing to gender-specific median values, forced vital capacity as a percent of pre-
dicted with missing values (27.11% missing) entered according to median
values, forced expiratory volume in 1 second as a percent of predicted with
missing values (22.81%missing) entered according to median values, carbon
monoxide diffusing capacity as a percent of predicted with missing values
(42.15% missing) entered according to median values]; binary variables
(0%missing) with all missing values defaulted to ‘‘no’’ per the STS database
[hypertension, preoperative thoracic radiation therapy, congestive heart fail-
ure, coronary artery disease, peripheral vascular disease, preoperative steroid
use steroid, current smoker (patient smokes or quit less than 1 month), cerebro-
vascular disease, diabetes, and renal insufficiency (dialysis or creatinine level
greater than 2)]; and categorical variables [Zubrod score (5.05% missing),
American Society of Anesthesiologists Risk Scale (7.92% missing), status
(clinical status of the patient at the time of the primary surgical procedure;
3.67% missing), and clinical (43% missing) and pathologic cancer stage
(23% missing)]. Clinical stage was not included in the model due to the sig-
nificant amount of missing data. Missing data variables were treated as above
to limit the introduction of bias by their exclusion.
Propensity scores were estimated using a logistic model including the
following variables: age, gender, Zubrod score, American Society of Anes-
thesiologists Risk Scale, body mass index, hypertension, coronary artery
disease, congestive heart failure, renal insufficiency, diabetes, current
smoker, preoperative chemotherapy or radiotherapy, cerebrovascular dis-
ease, steroid use, clinical status, forced vital capacity as a percent of pre-
dicted, forced expiratory volume in 1 second as a percent of predicted,
and carbon monoxide diffusing capacity as a percent of predicted. Patients
were then matched using a Greedy 5 to 1 digit matching algorithm.17 Miss-
ing values in Zubrod score, American Society of Anesthesiologists Risk
Scale, and clinical status were kept as separate levels. Standardized differ-
ence [(X2 X1)/((S22þ S12)/2)1/2, where X1 and X2 are samples means in
the thoracotomy and groups, respectively, and S2
2þS12 are the sample stan-
dard deviations] was used to assess significance in differences of preopera-
tive variables as well as clinical and pathologic staging between the 2 groups
(>20 and<20 being significantly different). Standardize difference was used
rather thanP value as it has been shown by others to not be sensitive to sample
size, asP value is, and hence better for propensity matching.18 Matching basedThe Journal of Thoracic and Caon propensity scores produced 1281 patients in each group for analysis of post-
operative outcomes (Table 1). Postoperative outcomes analyzed for each
group were assessed for significance (P values) based on McNemar tests
(matched comparison) or Pearson chi-square (unmatched comparison) for cat-
egorical outcomes and Wilcoxon signed–rank tests for continuous outcomes
with significance adjusted for Bonferroni correction where needed (Table
2). Postoperative outcomes as well as clinical and pathologic staging of the un-
matched cohort of 6323 patients can be found in the appendix for comparison
(Appendix Tables 2–5). Analysis was performed using S-Plus 6 (Insightful
Corp, Seattle, WA) and SAS 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
The baseline characteristics of the 1281 patients in each
group who were derived by propensity matching from the
initial cohort of 6323 patients are shown in Table 1. A total
of 83 centers participating in the STS-GTD contributed
patients to these matched groups (70 having VATS, 83
having thoracotomy). The contribution from each center
can be found in Appendix Table 2. As designed, the baseline
characteristics of the 2 cohorts are statistically similar for the
preoperative variables used for propensity matching.
The clinical and pathologic stages for the matched cohorts
are shown in Table 2. Clinical staging information was miss-
ing in a large number of patients in both groups including
430 patients (33.6%) who had VATS lobectomy and 591
patients (46.1%) who had an open lobectomy. There was
no statistically significant difference in the pathologic stage
distribution between the 2 groups, with the majority of
lobectomies performed for pathologic stage I disease.
Thus, although clinical and pathologic stages were not
included in the propensity matching analysis, the final
pathologic stage distribution in the 2 groups is similar.Perioperative Mortality and Morbidity
Analysis of the propensity-matched groups for postoper-
ative outcomes demonstrated that VATS lobectomy was
associated with significantly lower morbidity: 945 patientsrdiovascular Surgery c Volume 139, Number 2 367
TABLE 1. Characteristics of patients having lobectomy (matched)
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
Standardized
difference*
Demographics
Age
Median 66.00 66.00 2.26
25th 57.00 58.00
75th 74.00 74.00
Mean  SD 64.83  12.1 65.10 12.1
Gender
Male 549 (42.86%) 540 (42.15%)
Female 732 (57.14%) 741 (57.85%) 1.42
Preoperative risk
factors
Zubrod Score
0 595 (46.45%) 576 (44.96%) 2.98
1 534 (41.69%) 562 (43.87%) 4.42
2 76 (5.93%) 75 (5.85%) 0.33
3 32 (2.50%) 29 (2.26%) 1.53
4 4 (0.31%) 5 (0.39%) 1.32
Missing 40 (3.12%) 34 (2.65%) 2.80
ASA risk class
I 59 (4.61%) 49 (3.83%) 3.88
II 360 (28.10%) 341 (26.62%) 3.33
III 723 (56.44%) 749 (58.47%) 4.10
IV 41 (3.20%) 47 (3.67%) 2.57
V 2 (0.16%) 1 (0.08%) 2.28
Missing 96 (7.49%) 94 (7.34%) 0.60
BMI (kg/m2)
Median 25.82 25.69 0.26
25th 23.03 22.97
75th 29.38 29.30
Mean  SD 26.55  5.33 26.56  5.33
Hypertension
No 681 (53.16%) 661 (51.60%)
Yes 600 (46.84%) 620 (48.40%) 3.13
Coronary artery disease
No 1109 (86.57%) 1097 (85.64%)
Yes 172 (13.43%) 184 (14.36%) 2.71
Congestive heart
failure
No 1248 (97.42%) 1254 (97.89%)
Yes 33 (2.58%) 27 (2.11%) 3.10
Renal insufficiency
No 1265 (98.75%) 1268 (98.99%)
Patient has any
history of diabetes
No 1164 (90.87%) 1140 (88.99%)
Yes 117 (9.13%) 141 (11.01%) 6.23
Current smoker or
quit<1 mo
Preoperatively
No 969 (75.64%) 956 (74.63%)
Yes 312 (24.36%) 325 (25.37%) 2.35
Preoperative
chemotherapy
No 1166 (91.02%) 1164 (90.87%)
TABLE 1. Continued
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
Standardized
difference*
Preoperative
x-ray therapy
No 1212 (94.61%) 1213 (94.69%)
Yes 69 (5.39%) 68 (5.31%) 0.35
Peripheral vascular
disease
No 1202 (93.83%) 1204 (93.99%)
Yes 79 (6.17%) 77 (6.01%) 0.65
Cerebrovascular
history
No 1178 (91.96%) 1160 (90.55%)
Yes 103 (8.04%) 121 (9.45%) 4.97
Steroids
No 1235 (96.41%) 1234 (96.33%)
Yes 46 (3.59%) 47 (3.67%) 0.42
Clinical status at
time of surgery
Emergent 2 (0.16%) 5 (0.39%) 4.49
Urgent 21 (1.64%) 15 (1.17%) 3.97
Elective 1241 (96.88%) 1248 (97.42%) 3.28
Missing 17 (1.33%) 13 (1.01%) 2.90
Pulmonary function
tests
FVC predicted
Median 89.00 89.00 1.96
25th 84.00 82.00
75th 98.00 100.00
Mean  SD 90.37  17.0 90.02  18.6
FEV predicted
Median 81.00 81.00 3.31
25th 77.00 73.00
75th 94.00 97.00
Mean  SD 83.88  19.6 83.20  21.5
DLCO predicted
Median 73.00 73.00 1.93
25th 73.00 69.00
75th 79.00 83.00
Mean  SD 75.94  18.7 75.58  18.6
ASA, American Society of Anesthesiologists Risk Scale; BMI, body mass index;
DLCO predicted, carbon monoxide diffusing capacity as a percent of predicted;
FEV predicted, forced expiratory volume in 1 second as a percent of predicted;
FVC predicted, forced vital capacity as a percent of predicted; SD, standard deviation.
*Standardized difference ¼ 100(X2 X1)/((S22þ S12)/2)1/2, X1 and X2 are samples
means in the thoracotomy and thoracoscopy groups respectively, and S2
2þ S12 are
the sample standard deviations. Differences less than20 and greater than 20 are sig-
nificant (at least P< .05).
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no complications, compared with 837 patients (65.3%) of
those who had lobectomy by thoracotomy (P < .0001).
There was no difference in operative mortality (Table 3).
Specific postoperative complications included in the STS-
GTSD are also compared in the 2 matched groups (Table 3).
Compared with lobectomy via thoracotomy, VATS lobec-
tomy was associated with a lower incidence of overallery c February 2010
TABLE 2. Clinical and pathologic staging of patients having
lobectomy (matched)
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
Standardized
difference*
Clinical cancer stage
Missing 591 (46.14%) 430 (33.57%) 25.87
Stage I A/B 470 (36.69%) 700 (54.64%) 36.63
Stage II A/B 80 (6.25%) 46 (3.59%) 12.29
Stage III A 44 (3.43%) 28 (2.19%) 7.56
Stage III B 9 (0.70%) 15 (1.17%) 4.86
Stage IV 15 (1.17%) 17 (1.33%) 1.41
Occult 1 (0.08%) 2 (0.16%) 2.28
Undefined 71 (5.54%) 43 (3.36%) 10.61
Pathologic cancer stage
Missing 279 (21.78%) 267 (20.84%) 2.29
Stage 0 1 (0.08%) 0 (0%) 3.95
Stage I A/B 676 (52.77%) 783 (61.12%) 16.92
Stage II A/B 162 (12.65%) 106 (8.27%) 14.32
Stage III A 89 (6.95%) 70 (5.46%) 6.15
Stage III B 36 (2.81%) 30 (2.34%) 2.96
Stage IV 21 (1.64%) 14 (1.09%) 4.71
Undefined 17 (1.33%) 11 (0.86%) 4.50
*Standardized difference ¼ 100(X2 X1)/((S22þ S12)/2)1/2, X1 and X2 are samples
means in the thoracotomy and thoracoscopy groups, respectively, and S2
2þ S12 are
the sample standard deviations. Differences less than20 and greater than 20 are sig-
nificant (at least P< .05).
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Spulmonary complications (7.6% vs 12.2%; P ¼ .0001).
Specific subgroup analysis showed that patients who had
VATS lobectomy had significantly fewer reintubations post-
operatively compared with those who had lobectomy via
thoracotomy.
Similarly, overall cardiovascular morbidity was signifi-
cantly lower in the VATS lobectomy group (8.3% vs
13.0%, P ¼ .0002), with a significant reduction noted in
atrial arrhythmias requiring treatment [93 patients (7.3%)
vs 147 patients (11.5%), P ¼ 0.0004]. There was no differ-
ence detected among other cardiovascular complications.
The frequency of blood transfusions was also signifi-
cantly lower following VATS lobectomy (2.4% vs 4.7%,
P ¼ .0028). Although the frequency of overall infectious
complications was lower after lobectomy, the difference
did not achieve statistical significance after Bonferroni ad-
justment for multiple comparisons.Operative Time, Chest Tube Duration, and Length of
Stay
Operative time, measured from the time of skin incision,
was higher for VATS lobectomy, with a median increase in
operative time of 30 minutes (median 173 vs 143 minutes, P
<.0001). Although the frequency of prolonged air leaks (>5
days) were similar for both cohorts (7.57% vs 8.67%, P ¼
.3531), VATS lobectomy was associated with earlier chest
tube removal (median 3 days vs 4 days, P< .0001; Table
4). Length of stay was also shorter by a median of 2 daysThe Journal of Thoracic and Cafor those having VATS lobectomy (median 4 days vs 6
days, P< .0001).
DISCUSSION
In this study, analyzing the incidence of postoperative com-
plications using a propensity-matched analysis of patients in
the STS-GTD, VATS lobectomy is associated with lower
postoperative morbidity compared with thoracotomy, with
a lower overall complication rate and lower rates of several in-
dividual complications, including atrial fibrillation. Although
the results of this study do not rise to the level 1 evidence ob-
tained from randomized trials, the propensity-matching anal-
ysis used in the current analysis reduces many of the biases
inherent in retrospective single-institution case series.
This study suggests that VATS lobectomy should be per-
formed in appropriately selected patients with lung cancer.
Notwithstanding a phase II trial conducted by the Cancer
and Leukemia Group B (CALGB 39802) demonstrating
the safety and feasibility of lobectomy,19 the acceptance of
VATS lobectomy into the national general thoracic practice
remains limited. In 2007, nearly 70% of all lobectomies
reported to the STS-GTD were still performed via open
thoracotomy (Figure 1).15 The lack of wider national and in-
ternational application of VATS lobectomy may be due to
the relatively steep learning curve required for the procedure,
the fact that most practicing surgeons did not learn the proce-
dure in training (including general surgeons who still per-
form lobectomy),20 and concerns regarding oncologic
efficacy. However, experience with this procedure has dem-
onstrated that it can be taught and practiced safely2,3,21 and
that the operation is at least as oncologically effective.2,3,22
The concept that thoracoscopic lobectomy may have
a lower complication profile has recently been analyzed in
single-institution series including patients having VATS
lobectomy and patients having open lobectomy. In 1 study,
122 patients having VATS lobectomy and 122 patients hav-
ing lobectomy by thoracotomy were compared.12 Overall,
the incidence of postoperative complications was lower in
the VATS group (17.2% vs 27.9%, P ¼ .046); however,
these patients were matched for age and sex only, and there
was no significant difference in the incidence of any of the
specific complications reported. In another study, limited to
the analysis of elderly patients, VATS lobectomy resulted
in a significantly lower rate of complications compared with
thoracotomy (28% vs 45%, P ¼ 0.04).13 However, this
series was limited to patients with clinical stage I non–
small-cell lung cancer, and the incidence of several specific
complications analyzed individually was not significantly dif-
ferent between the 2 groups. A propensity analysis of a larger
group of patients from these series demonstrated a numerical,
but not statistically significant, improvement in survival.23
In a larger study comparing outcomes of VATS lobec-
tomy compared with thoracotomy, a propensity-matched
analysis based on preoperative variables and stage asrdiovascular Surgery c Volume 139, Number 2 369
TABLE 3. Postoperative outcomes of patients having lobectomy
(matched)
Postoperative
outcomes
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
P
value*
Any complication
No 837 (65.34%) 945 (73.77%) <.0001y
Yes 444 (34.66%) 336 (26.23%)
Death (discharge or 30-d)
No 1268 (98.99%) 1269 (99.06%) 1.0000
Yes 13 (1.01%) 12 (0.94%)
Pulmonary complications
Any pulmonary
complication
No 1125 (87.82%) 1184 (92.43%) .0001y
Yes 156 (12.18%) 97 (7.57%)
Air leak duration>5 d
No 1170 (91.33%) 1184 (92.43%) .3531
Yes 111 (8.67%) 97 (7.57%)
Atelectasis requiring
bronchoscopy
No 1239 (96.72%) 1254 (97.89%) .0722
Yes 42 (3.28%) 27 (2.11%)
Pneumonia
No 1225 (95.63%) 1243 (97.03%) .0758
Yes 56 (4.37%) 38 (2.97%)
Evidence of adult
respiratory distress
syndrome
No 1271 (99.22%) 1272 (99.30%) 1.0000
Yes 10 (0.78%) 9 (0.70%)
Bronchopleural fistula
No 1279 (99.84%) 1278 (99.77%) 1.0000
Yes 2 (0.16%) 3 (0.23%)
Pulmonary embolus
No 1278 (99.77%) 1278 (99.77%) 1.0000
Yes 3 (0.23%) 3 (0.23%)
Initial ventilatory
support>48 h
No 1274 (99.45%) 1275 (99.53%) 1.0000
Yes 7 (0.55%) 6 (0.47%)
Reintubation
No 1241 (96.88%) 1263 (98.59%) .0046y
Yes 40 (3.12%) 18 (1.41%)
Tracheostomy
No 1268 (98.99%) 1270 (99.14%) .8388
Yes 13 (1.01%) 11 (0.86%)
Other pulmonary event
No 1221 (95.32%) 1249 (97.50%) .0042y
Yes 60 (4.68%) 32 (2.50%)
Cardiovascular complications
Any cardiovascular
complication
No 1114 (86.96%) 1175 (91.73%) .0002y
Yes 167 (13.04%) 106 (8.27%)
Atrial arrhythmia
requiring treatment
No 1134 (88.52%) 1188 (92.74%) .0004y
TABLE 3. Continued
Postoperative
outcomes
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
P
value*
Yes 147 (11.48%) 93 (7.26%)
Ventricular arrhythmia
requiring treatment
No 1274 (99.45%) 1275 (99.53%) 1.0000
Yes 7 (0.55%) 6 (0.47%)
Myocardial infarct
No 1280 (99.92%) 1280 (99.92%) 1.0000
Yes 1 (0.08%) 1 (0.08%)
DVT requiring treatment
No 1277 (99.69%) 1279 (99.84%) .6875
Yes 4 (0.31%) 2 (0.16%)
Other cardiovascular event
No 1263 (98.59%) 1271 (99.22%) .1849
Yes 18 (1.41%) 10 (0.78%)
Hematologic complications
Any hematologic
complication
No 1213 (94.69%) 1239 (96.72%) .0158y
Yes 68 (5.31%) 42 (3.28%)
Bleeding requiring
reoperation
No 1274 (99.45%) 1265 (98.75%) .0931
Yes 7 (0.55%) 16 (1.25%)
Postoperative blood
transfusion
No 1221 (95.32%) 1250 (97.58%) .0028y
Yes 60 (4.68%) 31 (2.42%)
Other hematology or
bleeding requiring
therapy
No 1278 (99.77%) 1279 (99.84%) 1.0000
Yes 3 (0.23%) 2 (0.16%)
Infection
Any infection
No 1233 (96.25%) 1255 (97.97%) .0141
Yes 48 (3.75%) 26 (2.03%)
Urinary tract infection
No 1251 (97.66%) 1265 (98.75%) .0541
Yes 30 (2.34%) 16 (1.25%)
Patient experienced
empyema requiring
therapy
No 1273 (99.38%) 1280 (99.92%) .0391
Yes 8 (0.62%) 1 (0.08%)
Wound infection
No 1278 (99.77%) 1278 (99.77%) 1.0000
Yes 3 (0.23%) 3 (0.23%)
Sepsis
No 1273 (99.38%) 1275 (99.53%) .7905
Yes 8 (0.62%) 6 (0.47%)
Other complications
Any gastrointestinal
complication
No 1256 (98.05%) 1264 (98.67%) .2800
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TABLE 3. Continued
Postoperative
outcomes
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
P
value*
Yes 25 (1.95%) 17 (1.33%)
Any neurologic
complication
No 1272 (99.30%) 1262 (98.52%) .0755
Yes 9 (0.70%) 19 (1.48%)
Any miscellaneous
complication
No 1219 (95.16%) 1228 (95.86%) .4519
Yes 62 (4.84%) 53 (4.14%)
DVT, Deep vein thrombosis. *P values are based on McNemar tests. ySignificant after
Bonferroni adjustment.
TABLE 4. Operative time, chest tube duration, and length of stay for
patients having lobectomy (matched)
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
P
value*
Duration from
skin incision (min)*
Median 143.00 173.00 <.0001
Mean  SD 158.63  73.7 179.53  75.3
Missing (%) 6.25 5.15
Chest tube duration (d)
Median 4.00 3.00 <.0001
Mean  SD 4.76  3.93 3.65  3.09
Missing (%) 3.28 8.67
Postoperative length of stay (d)*
Median 6.00 4.00 <.0001
Mean  SD 7.16  7.08 5.31  5.95
Missing (%) 1.09 3.59
SD, Standard deviation. *P values are based on McNemar tests for categorical out-
comes and Wilcoxon signed–rank tests for continuous outcomes; significant after
Bonferroni adjustment.
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Sperformed, comparing 284 patients in each group.14 In this
study, 69% of those who had VATS lobectomy had no com-
plications, versus 51% who had thoracotomy (P ¼ .0001).
In addition, VATS lobectomy was associated with a lower
incidence of atrial fibrillation (13% vs 21%; P ¼ .01),
less atelectasis (5% vs 12%; P ¼ .006), fewer prolonged
air leaks (13% vs 19%; P ¼ .05), fewer transfusions (4%
vs 13%; P ¼ .002), less pneumonia (5% vs 10%; P ¼
.05), less renal failure (1.4% vs 5%; P ¼ .02), shorter chest
tube duration (median 3 vs 4 days; P< .0001), and shorter
length of hospital stay (median 4 vs 5 days; P< .0001).14
In this study, VATS lobectomy was associated with
fewer overall complications, as well as with specific com-
plications that are recognized to have an important impact
on cost and outcome. The frequency of postoperative atrial
arrhythmias has now been demonstrated to be significantly
lower after thoracoscopic lobectomy. Atrial fibrillation is
a significant source of morbidity after cardiothoracic sur-
gery and often prolongs hospital stay by requiring the
need for extended telemetry monitoring, anticoagulation,
or pharmacologic cardioversion.24,25 The lower incidence
of atrial arrhythmias after VATS lobectomy may be due
to decreased levels of cytokines and other inflammatory
immunodulators released after thoracoscopic techniques
compared with thoracotomy.26
The results of the current analysis also demonstrate that
the incidence of postoperative pulmonary complications
were significantly lower after VATS lobectomy (7.6%
vs 12.2%). In particular, the need for reintubation was
less frequent after lobectomy compared with lobectomy
by thoracotomy, but the incidence of other complications
was not statistically different in the 2 groups. Although
the reason for this reduction is unclear, it may be due to
optimal postoperative pain control in the VATS lobectomy
group, which has been demonstrated in numerous stud-
ies.4,5,8,9 As the use of epidural anesthesia and postopera-
tive pain scores were not recorded in the STS-GTD, this
cannot be confirmed by this study. In addition, thoraco-
scopic lobectomy is associated with a lower transfusion
rate, a lower postoperative infection rate, shorter chestThe Journal of Thoracic and Catube duration, and shorter length of stay, compared with
thoracotomy by lobectomy.
The impact of VATS lobectomy on postoperative morbid-
ity in our cohort of 2562 patients may have been underesti-
mated by the relatively young age and the lack of major
cardiopulmonary comorbidity in patients in both cohorts.
The majority of patients were free of coronary artery disease
(>85%), congestive heart failure (>95%), and renal insuffi-
ciency (>98%), and both groups had relatively well-pre-
served pulmonary function. A recent analysis of the
Surveillance, Epidemiology, and End-Results (SEER)–
Medicare database from 1992 to 2002, showed that patients
with resectable lung cancer are now older (median age: 67
years) and more frequently present with significant comor-
bidities.26,27 Given these trends, VATS lobectomy may
be of even greater benefit in a population that is typically
older and with more comorbidities than our study popula-
tion.4,28
The demonstration of reduced complications after
VATS lobectomy should have important ramifications in
the care of patients after lobectomy. VATS lobectomy is
associated with a lower overall incidence of complications,
as well as a reduction of several specific complications,
suggesting that VATS lobectomy may actually be a safer
operation in appropriately selected patients. In addition,
the minimally invasive approach should offer important
economic advantages, as the management of postoperative
complications will significantly increase the cost of surgi-
cal management. Furthermore, considering that VATS lo-
bectomy is also associated with a shorter length of stay,
the apparent comparative effectiveness of VATS lobec-
tomy is further magnified.
We recognize that there are important limitations to this
analysis. Although propensity matching reduces the biasrdiovascular Surgery c Volume 139, Number 2 371
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equivalent to a prospective, randomized trial. In this volun-
tary data set, over 10% of patients had missing entry of pre-
operative variables, including demographics, pulmonary
function tests, and clinical stage. In general, patients with
missing data were not excluded from analysis to prevent
the introduction of an unknown confounder. Clinical stage
was not used in the matching process as a significant portion
of these data were also missing in both groups, as shown in
Table 2. Although there was a statistically higher portion of
clinical stage I patients in the VATS group, the proportion of
clinical stage I and II patients were statistically similar be-
tween the 2 groups, which is the cohort of patients in which
VATS lobectomy are typically performed. Although not
used in the matching algorithm, there was no difference in
overall pathologic stage distribution between the 2 groups.
Of note, 2 separate propensity scoring models incorporating
clinical and pathologic stage as well as another model ex-
cluding patients with missing clinical stage data yielded sim-
ilar results (data not shown).
Other limitations in our analysis result from weaknesses
inherent in any large national database. This includes the
inability to discern within the STS-GTD which patients
in the thoracoscopy group were converted to thoracotomy
intraoperatively. Hence, an intention-to-treat analysis can-
not be performed. Our 2 groups to the best of our knowl-
edge represent a cohort that had either VATS or
thoracotomy for lobectomy. It is unclear if the 17 patients
excluded from the analysis for being listed as both thora-
coscopy and thoracotomy represent this group of patients
who had intraoperative conversion, as operative notes are
not available. If it indeed does, the rate of conversion
would be exceedingly low and not consistent with the lit-
erature. An additional limitation results that the STS data-
base does not mandate technique and hence variances in
VATS techniques such as number and sites of ports, the
use of rib spreader, and the extent of mediastinal lympha-
denectomy performed cannot be controlled at each partici-
pating center. However, no one center contributed
disproportionately to the 1281 matched group of patients
(Appendix Table 1), with no center contributing more
than 99 patients to the VATS group or 131 patients to
the thoracotomy group. Hence, the results are not skewed
by the results of one center exceptionally facile with
VATS techniques. A separate analysis examining risks
factors for complications after VATS lobectomy will fur-
ther assess these factors (hospital type and volume) in
VATS outcomes.
Furthermore, as complications are self-reported in the
STS database, they may be underreported and hence skew
our results. As the trend toward VATS lobectomy is a self-
directed effort by surgeons to improve outcomes, an inherent
bias may be to minimize complications, facilitate chest tube
removal, and hence discharge. Additionally, our analysis372 The Journal of Thoracic and Cardiovascular Surgalso does not include long-term outcomes, as the STS-
GTD does not maintain these data. Thus, the long-term
effect of the improved postoperative outcomes cannot be
determined.
In conclusion, this propensity-matched study of patients
in the STS-GTSD found VATS lobectomy to be associated
with a lower incidence of multiple postoperative complica-
tions compared with lobectomy by thoracotomy, as well as
decreased chest tube duration and length of stay. In lieu of
a randomized control trial comparing thoracotomy and thor-
acoscopy for lobectomy, this study provides the best avail-
able evidence regarding outcomes after VATs lobectomy.
VATs lobectomy may be the preferred strategy for appropri-
ately selected patients with lung cancer.References
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Discussion
Dr Neil Christie (Pittsburgh, Pa). I have no conflicts to disclose.
Earlier studies in thoracoscopic lobectomy focused on feasibility
and technique. That having been established, there is now an inter-
est to determine if it is superior to the open thoracotomy technique
and, as such, should become the standard of care. This paper has
demonstrated a significant decrease in perioperative complications
and a shortened length of stay with the thoracoscopic approach to
lobectomy.
I would now like to ask a few questions. First, all thoracoscopic
lobectomy series have a subset of patients in whom conversion to
thoracotomy is required, occasionally due to intraoperative compli-
cations such as bleeding. In your analysis, it would seem that these
conversion cases are not included in the thoracoscopic group, po-
tentially biasing your study in favor of thoracoscopy. Could you
please comment on this?
Dr Subroto Paul (New York, NY). Excellent question. There
were patients who were excluded, 17 patients in total, who had
VATS lobectomy as well as thoracotomy listed as a procedure per-
formed. Looking at the STS database, it is difficult to ascertain
which patients were conversion cases and trying to keep them as
an intent-to-treat analysis. So we did exclude those patients, and
these are a pure group of patients who just had completed
a VATS lobectomy versus an open thoracotomy lobectomy. It
does introduce bias and, hence, why this trial is not the equivalent
of a randomized trial with an intention-to-treat analysis.The Journal of Thoracic and CaDr Christie. My second question is, some authors recommend
thoracoscopic lobectomy only for stage I node-negative cancers
due to the potential of increased difficulty of resection with en-
larged lymph nodes. Your study included patients with stage II
and stage III cancer. Were you able to do a subset analysis of out-
comes with clinical stage II and stage III lung cancers, and would
you recommend the thoracoscopic approach as being optimal in
these patients?
Dr Paul. A separate analysis was performed using clinical stage
as a preoperative variable and including only clinical stage I and
stage II patients, and the outcomes were very similar, with the
same rates of lower atrial fibrillation, reintubation.
In terms of the second question, could you elaborate a little bit
more?
Dr Christie. In that subset of patients who had more advanced
disease and clinical nodal disease, do you think the complication
rates would still be lower than that seen with thoracotomy?
Dr Paul. It seems from our data that if you had a VATS lobec-
tomy, even for a higher-stage disease, your complication rates are
lower, and that is supported by several other single-institution stud-
ies. Further analysis of the data would be needed just to look at that
subset.
Dr Christie. My final question is, acknowledging the potential
selection bias in your study, would you and your colleagues recom-
mend that a prospective randomized study be undertaken of thora-
coscopic lobectomy versus open thoracotomy?
Dr Paul. Well, the gold standard would be to have a randomized
trial, but the number of patients that would need to be recruited
would be in excess of probably 1000 in each arm to show some
of these complications, so it would be difficult to perform and con-
duct. I don’t think it will ever be done, but it probably should be
done.
Thank you.
Dr David Cooke (Sacramento, Calif). Very good presentation,
Subroto.
I have a couple questions. One, did you match the thoracoscopic
group and the open lobectomy group with patients having medias-
tinal lymph node sampling or dissections? The assumption is that
most of these patients probably did have mediastinal lymph node
sampling or dissection, but from previous studies, it’s not 100%.
In fact, there is a good percentage of patients who do not have sam-
pling or dissection. That might affect possibly the length of chest
tube duration, among other outcomes.
Dr Paul. Excellent question. We are kind of limited by the da-
tabase, which does not include dissection versus sampling within
the study, so that is not included as part of the matching process,
and that may have affected the results. I think that is one of the ques-
tions that we’re trying to get at through indirect means through the
STS database.
DrCooke. The second question is, did you look at differences in
terms of intensive care unit admissions and hospital readmissions
between the 2 groups?
Dr Paul. That is also another excellent question. Those are pa-
rameters that are not included in the STS database, so we could not
look at them.
Dr Raja Flores (New York, NY). Nice study, Subroto. I have
a word of caution, though. I think when one looks at conver-
sion, it seems as if the ascertainment of the data for the STSrdiovascular Surgery c Volume 139, Number 2 373
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converted. If you look at the data, you had 17 patients who had
both thoracoscopy and thoracotomy out of 1300. Potentially
those are conversions. It’s not known for sure. If those are con-
versions, that number is very small. If you look at the prospec-
tive study, the CALGB trial, of surgeons who are technically
very facile in doing VATS lobectomy, their conversion rate
was 14%. So for the database, I think that’s low. And whenever
you have a group of patients who are converted, the proper374 The Journal of Thoracic and Cardiovascular Surganalysis is not to exclude them but to include them in the
VATS lobectomy group so as to minimize any bias in favor
of VATS. Overall, I think it was an excellent study based on
the data available, but I think there are some major limitations
with the ascertainment of the data for the database that limit
the conclusions of this study.
Dr Paul. I agree with your point. There are some things that
were limited by the database in terms of what information we can
get out of it.ery c February 2010
APPENDIX TABLE 1. Characteristics of patients having lobectomy
(unmatched)
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281)
Standardized
difference*
Demographics
Age
Median 67.00 66.00 0.93
25th 58.00 58.00
75th 74.00 74.00
Mean  SD 64.99  12.1 65.10  12.1
Gender
Male 2439 (48.37%) 540 (42.15%)
Female 2603 (51.63%) 741 (57.85%) 1.42
Preoperative risk
factors
Zubrod score
0 2131 (42.26%) 576 (44.96%) 5.45
1 2234 (44.31%) 562 (43.87%) 0.88
2 274 (5.43%) 75 (5.85%) 1.82
3 91 (1.80%) 29 (2.26%) 3.25
4 22 (0.44%) 5 (0.39%) 0.72
5 5 (0.10%) 0 (0%) 4.46
Missing 285 (5.65%) 34 (2.65%) 15.07
ASA risk class
I 100 (1.98%) 49 (3.83%) 10.98
II 1237 (24.53%) 341 (26.62%) 4.78
III 2799 (55.51%) 749 (58.47%) 5.97
IV 492 (9.76%) 47 (3.67%) 24.51
V 7 (0.14%) 1 (0.08%) 1.85
Missing 407 (8.07%) 94 (7.34%) 2.75
BMI (kg/m2)
Median 26.40 25.69 10.85
25th 23.59 22.97
75th 29.80 29.30
Mean  SD 27.17  5.84 26.56  5.33
Hypertension
No 2418 (47.96%) 661 (51.60%)
Yes 2624 (52.04%) 620 (48.40%) 7.29
Coronary artery
disease
No 4211 (83.52%) 1097 (85.64%)
Yes 831 (16.48%) 184 (14.36%) 5.86
Congestive
heart failure
No 4920 (97.58%) 1254 (97.89%)
Yes 122 (2.42%) 27 (2.11%) 2.10
Renal
insufficiency
No 4918 (97.54%) 1268 (98.99%)
Yes 124 (2.46%) 13 (1.01%) 11.07
Patient has any
history
of diabetes
No 4380 (86.87%) 1140 (88.99%)
Yes 662 (13.13%) 141 (11.01%) 6.52
APPENDIX TABLE 1. Continued
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281)
Standardized
difference*
Current smoker
or quit<1 mo
preoperatively
No 3600 (71.40%) 956 (74.63%)
Yes 1442 (28.60%) 325 (25.37%) 7.28
Preoperative
chemotherapy
No 4382 (86.91%) 1164 (90.87%)
Yes 660 (13.09%) 117 (9.13%) 12.61
Preoperative x-ray
therapy
No 4382 (86.91%) 1213 (94.69%)
Yes 443 (8.79%) 68 (5.31%) 13.62
Peripheral
vascular
disease
No 4614 (91.51%) 1204 (93.99%)
Yes 428 (8.49%) 77 (6.01%) 9.56
Cerebrovascular
history
No 4593 (91.09%) 1160 (90.55%)
Yes 449 (8.91%) 121 (9.45%) 1.87
Steroids
No 4860 (96.39%) 1234 (96.33%)
Yes 182 (3.61%) 47 (3.67%) 0.32
Clinical status
at time of
surgery
Emergency 28 (0.56%) 5 (0.39%) 2.41
Urgent 311 (6.17%) 15 (1.17%) 26.81
Elective 4484 (88.93%) 1248 (97.42%) 34.16
Missing 219 (4.34%) 13 (1.01%) 20.72
Pulmonary function
tests
FVC predicted
Median 89.00 89.00 8.94
25th 81.00 82.00
75th 95.00 100.00
Mean  SD 88.13  16.6 90.02  18.6
FEV1 predicted
Median 81.00 81.00 11.40
25th 72.00 73.00
75th 90.00 97.00
Mean  SD 80.44  18.9 83.20  21.5
DLCO predicted
Median 73.00 73.00 11.90
25th 70.00 69.00
75th 75.00 83.00
Mean  SD 72.86  18.7 75.58  18.6
ASA, American Society of Anesthesiologists Risk Scale; BMI, body mass index; FVC
predicted, forced vital capacity as a percent of predicted; FEV1 predicted, forced ex-
piratory volume in 1 second as a percent of predicted; DLCO predicted, carbon mon-
oxide diffusing capacity as a percent of predicted; SD, standard deviation.
*Standardized difference ¼ 100(X2 X1)/((S22þ S12)/2)1/2, X1 and X2 are samples
means in the thoracotomy and thoracoscopy groups, respectively, and S2
2þ S12 are
the sample standard deviations. Differences less than20 and greater than 20 are sig-
nificant (at least P< .05).
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APPENDIX TABLE 2. Distribution of lobectomies performed by
participating STS center
Center
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
1 0 99
2 10 93
3 131 92
4 4 81
5 77 80
6 19 62
7 13 55
8 8 51
9 20 49
10 14 46
11 14 46
12 5 35
13 1 35
14 30 31
15 7 30
16 8 27
17 33 26
18 13 25
19 1 25
20 15 21
21 11 21
22 39 15
23 91 14
24 9 14
25 0 14
26 2 13
27 1 13
28 26 12
29 22 12
30 4 11
31 1 10
32 26 8
33 14 8
34 11 8
35 0 8
36 50 6
37 2 6
38 38 5
39 15 5
40 10 5
41 5 5
42 3 5
43 2 5
44 3 4
45 2 4
46 31 3
47 19 3
48 8 3
49 2 3
50 1 3
51 48 2
52 47 2
53 22 2
APPENDIX TABLE 2. Continued
Center
Thoracotomy
(n ¼ 1281)
Thoracoscopy
(n ¼ 1281)
54 9 2
55 8 2
56 2 2
57 30 1
58 20 1
59 14 1
60 12 1
61 11 1
62 10 1
63 8 1
64 5 1
65 4 1
66 4 1
67 3 1
68 3 1
69 1 1
70 0 1
71 17 0
72 17 0
73 16 0
74 16 0
75 15 0
76 13 0
77 13 0
78 9 0
79 7 0
80 6 0
81 5 0
82 5 0
83 3 0
84 2 0
85 2 0
86 2 0
87 1 0
STS, Society of Thoracic Surgeons.
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APPENDIX TABLE 3. Clinical and pathologic staging of patients
having lobectomy (unmatched)
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281)
Standardized
difference*
Clinical cancer stage
Missing 2261 (44.84%) 430 (33.57%) 23.25
Stage I A/B 1823 (36.16%) 700 (54.64%) 37.78
Stage II A/B 327 (6.49%) 46 (3.59%) 13.26
Stage III A 221 (4.38%) 28 (2.19%) 12.35
Stage III B 64 (1.27%) 15 (1.17%) 0.90
Stage IV 79 (1.57%) 17 (1.33%) 2.01
Occult 3 (0.08%) 2 (0.16%) 2.94
Undefined 264 (5.24%) 43 (3.36%) 9.28
Pathologic cancer
stage
Missing 1196 (23.72%) 267 (20.84%) 6.92
Stage 0 2 (0.04%) 0 (0%) 2.82
Stage I A/B 2524 (50.06%) 783 (61.12%) 22.40
Stage II A/B 645 (12.79%) 106 (8.27%) 14.75
Stage III A 375 (7.44%) 70 (5.46%) 8.04
Stage III B 127 (2.52%) 30 (2.34%) 1.15
Stage IV 96 (1.90%) 14 (1.09%) 6.68
Occult 7 (0.14%) 0 (0%) 5.27
Undefined 17 (1.39%) 11 (0.86%) 5.03
*Standardized difference ¼ 100(X2 X1)/((S22þ S12)/2)1/2, X1 and X2 are samples
means in the thoracotomy and thoracoscopy groups, respectively, and S2
2þ S12 are
the sample standard deviations. Differences less than20 and greater than 20 are sig-
nificant (at least P< .05).
APPENDIX TABLE 4. Postoperative outcomes of patients having
lobectomy (unmatched)
Postoperative
outcomes
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281)
P
value*
Any complication
occurred?
No 3254 (64.54%) 945 (73.77%) <.0001y
Yes 1788 (35.46%) 336 (26.23%)
Death (discharge or 30-d)
No 4973 (98.63%) 1269 (99.06%) .2199
Yes 69 (1.37%) 12 (0.94%)
Pulmonary complications
Any pulmonary
complication
occurred?
No 4438 (88.02%) 1184 (92.43%) .0001y
Yes 604 (11.98%) 97 (7.57%)
Air leak duration>5 d
No 4573 (90.70%) 1184 (92.43%) .0528
Yes 469 (9.30%) 97 (7.57%)
Atelectasis requiring
bronchoscopy
No 4860 (96.39%) 1254 (97.89%) .0073
Yes 182 (3.61%) 27 (2.11%)
Pneumonia
No 4824 (95.68%) 1243 (97.03%) .0278
Yes 218 (4.32%) 38 (2.97%)
Evidence of adult
respiratory distress
syndrome
No 4991 (98.99%) 1272 (99.30%) .3085
Yes 50 (1.01%) 9 (0.70%)
Bronchopleural fistula
No 5026 (99.68%) 1278 (99.77%) .6274
Yes 16 (0.32%) 3 (0.23%)
Pulmonary embolus
No 5019 (99.54%) 1278 (99.77%) .2676
Yes 23 (0.46%) 3 (0.23%)
Initial ventilatory
support>48 h
No 5002 (99.21%) 1275 (99.53%) .2217
Yes 40 (0.79%) 6 (0.47%)
Reintubation
No 4880 (96.79%) 1263 (98.59%) .0005y
Yes 162 (3.21%) 18 (1.41%)
Tracheostomy
No 4975 (98.67%) 1270 (99.14%) .1735
Yes 67 (1.33%) 11 (0.86%)
Other pulmonary
event
No 4848 (85.72%) 1249 (97.50%) .0202
Yes 720 (14.28%) 32 (2.50%)
CV complications
Any CV complication
occurred?
No 4322 (85.72%) 1175 (91.73%) <.0001y
Yes 720 (14.28%) 106 (8.27%)
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APPENDIX TABLE 4. Continued
Postoperative
outcomes
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281)
P
value*
Atrial arrhythmia
requiring treatment
No 4426 (87.78%) 1188 (92.74%) <.0001y
Yes 616 (12.22%) 93 (7.26%)
Ventricular arrhythmia
requiring treatment
No 5003 (99.23%) 1275 (99.53%) .2461
Yes 39 (0.77%) 6 (0.47%)
Myocardial infarct
No 5028 (99.72%) 1280 (99.92%) .1898
Yes 14 (0.28%) 1 (0.08%)
DVT requiring
treatment
No 5016 (99.48%) 1279 (99.84%) .0835
Yes 26 (0.52%) 2 (0.16%)
Other cardiovascular
event
No 4961 (98.39%) 1271 (99.22%) .0267
Yes 81 (1.61%) 10 (0.78%)
Hematologic
complications
Any hematologic
complication
No 4726 (98.39%) 1239 (96.72%) <.0001y
Yes 81 (1.61%) 42 (3.28%)
Bleeding requiring
reoperation
No 5008 (99.33%) 1265 (98.75%) .0381
Yes 34 (0.67%) 16 (1.25%)
Postoperative blood
transfusion
No 4759 (94.39%) 1250 (97.58%) <.0001y
Yes 283 (5.61%) 31 (2.42%)
Other hematology or
bleeding requiring
therapy
No 5023 (99.62%) 1279 (99.84%) .2202
Yes 19 (0.38%) 2 (0.16%)
Infection
Any infection
No 4886 (96.91%) 1255 (97.97%) .0419
Yes 156 (3.09%) 26 (2.03%)
Urinary tract infection
No 4957 (98.31%) 1265 (98.75%) .2655
Yes 85 (1.69%) 16 (1.25%)
Patient experienced
empyema
requiring
therapy
No 5017 (99.50%) 1280 (99.92%) .0369
Yes 25 (0.50%) 1 (0.08%)
Wound infection
No 5023 (99.62%) 1278 (99.77%) .4388
Yes 19 (0.38%) 3 (0.23%)
APPENDIX TABLE 4. Continued
Postoperative
outcomes
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281)
P
value*
Sepsis
No 4999 (99.15%) 1275 (99.53%) .1612
Yes 43 (0.85%) 6 (0.47%)
Other complications
Any gastrointestinal
complication
No 4925 (97.68%) 1264 (98.67%) .0275
Yes 117 (2.32%) 17 (1.33%)
Any neurologic
complication
No 4943 (98.04%) 1262 (98.52%) .2567
Yes 99 (1.96%) 19 (1.48%)
Any miscellaneous
complication
No 4699 (93.20%) 1228 (95.86%) .0004y
Yes 343 (6.80%) 53 (4.14%)
CV, Cerebrovascular; DVT, deep vein thrombosis. *P values are based on Pearson chi-
square tests. ySignificant after Bonferroni adjustment.
APPENDIX TABLE 5. Operative time, chest tube duration, and
length of stay for patients having lobectomy (unmatched)
Thoracotomy
(n ¼ 5042)
Thoracoscopy
(n ¼ 1281) P value*
Duration of skin
incision (min)*
Median 144.00 173.00 <.0001
Mean  SD 159.10  74.5 179.53  75.3
Missing (%) 9.94 5.15
Chest tube
duration (d)
Median 4.00 3.00 <.0001
Mean  SD 4.61  4.01 3.65  3.09
Missing (%) 5.31 8.67
Postoperative length
of stay (d)*
Median 6.00 4.00 <.0001
Mean  SD 7.44  7.12 5.31  5.95
Missing (%) 1.59 3.59
SD, Standard deviation. *P values are based on Pearson chi-square tests for categorical
outcomes and Wilcoxon signed–rank tests for continuous outcomes; significant after
Bonferroni adjustment.
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